MEA HPV Testing and Pap Test Market Research Report – Segmented By Application, Test Type, End User and Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) - Industry Size, Share, Trends and Growth Forecast (2024 to 2029)

Updated On: January, 2024
ID: 3626
Pages: 145

MEA HPV Testing and Pap Test Market Size (2022 to 2027)

The size of the HPV Testing and Pap Test Market in Latin America was around USD 0.28 million in 2022. It is expected to grow at a CAGR of 5.5% to reach USD 0.37 million by 2027. It captures 7% of the global market.

Factors that can help limit cervical cancer are prevention and early detection with appropriate treatment. Primary prevention of cervical cancer uses HPV vaccination to prevent women from getting infected with oncogenic HPC, the leading cause of most cervical cancers. Secondary prevention of cervical cancer is done by using cervical screening to identify and treat abnormalities in the precancerous stage. Early detection shows positive outcomes with a longer lifespan, lesser complication, and reduced remission rare. The repetition of the screening test at specified review periods allows excellent accuracy for detecting precancerous growth of the squamous cell carcinoma of the cervix and the uterus. Screening for cervical cancer is an essential part of a woman's routine health care, aged 25 years of age and older, an HPV test is recommended.

The growing number of cervical cancer cases is increasing the demand for screening programs. According to the World Health Organization, more than 285,000 women die from cervical cancer each year. The estimated incidence of cervical cancer was 13.5per 100,000 women worldwide, with an average of 2 to 75 per 100,000 women. Cervical cancer is the leading cause of cancer death among women in East, West, Central, and Southern Africa. Data from Egyptian studies estimate the varying prevalence of invasive cervical cancer lesions ranging from 1% to 8% with an age range of 20 to 60 years. According to data collected from the Egyptian National Cancer Institute, invasive cancerous lesions account for 59.77% of all malignant tumors of the female genital tract. According to the WHO, the incidence of cervical cancer in Saudi Arabia is 2.2 / 100,000 women. These numbers are anticipated to grow over the many years, which will increase the demand for HPV testing and Pap smear tests in the MEA region.

Currently, Conventional tests are replaced with specific HPV DNA tests, which are technologically advanced test kits, like the Capture 2 test, which detects the presence of 13 high-risk types of HPV in the cervical sample. Hence, all of these factors have impacted the overall growth of the MEA HPV testing and Pap test market.

However, factors such as the uncertain changes in regulatory guidelines for cervical cancer screening and awareness and availability of the HPV vaccination are expected to limit the market growth rate. In addition, certain areas in the MEA region will challenge the market due to lack of awareness coupled with inadequate healthcare facilities, especially for female well-being.

This research report on the Middle East and Africa HPV Testing and Pap Test Market has been segmented and sub-segmented into the following categories:

By Test Type:

  • HPV Testing
  • Follow-up HPV Testing
  • HPV Primary Testing
  • Co-Testing
  • PAP Test

By Application:

  • Vaginal Cancer Screening
  • Cervical Cancer Screening

By End-users:

  • Laboratories
  • Hospitals
  • Physicians
  • Offices
  • Clinics

By Country:

  • KSA
  • UAE
  • Israel
  • rest of GCC countries
  • South Africa
  • Ethiopia
  • Kenya
  • Egypt
  • Sudan
  • rest of MEA

In 2020, the Middle Eastern market dominated the MEA HPV testing and Pap test market. The regional market in Saudi Arabia is anticipated to reach a market value of over $ 135 million by 2028. The regional market in the UAE will grow at a CAGR of 8.2% from 2022 - 2028. At the same time, the African region will have a small share in the overall market, anticipated to grow at a compound annual rate of 4.2% during the period 2022 - 2028. Factors such as a predominantly female population, favorable healthcare awareness programs, and improving healthcare facilities will drive the market in this region. The local authorities are providing comprehensive female programs to prevent breast and cervical cancer with screening and vaccinations. In addition, the increasing adoption of auto sampling for the detection of cervical cancer is also expected to contribute significantly to the growth. Self-sampling for HPV has the potential to overcome several identified barriers, such as cultural beliefs and social stigma.


Companies playing a notable role in the MEA HPV Testing and PAP Test Market profiled in this report are Abbott Laboratories, Qiagen N.V., Roche Diagnostics, Hologic, Inc., Becton, Dickinson and Company, Quest Diagnostics, Onco Health Corporation, Seegene, Inc., Femasys Inc., and Arbor Vita Corporation.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1200

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample